Videoconference-Based Cognitive Behavioral Therapy in Medication-Treated Adults with Attention-Deficit/Hyperactivity Disorder: A Randomized, Assessor-Blinded, Controlled Trial.

IF 16.3 1区医学 Q1 PSYCHIATRY

Psychotherapy and Psychosomatics Pub Date : 2025-06-05 DOI:10.1159/000546539

Aiko Eto, Ayumu Endo, Tokiko Yoshida, Yoichi Seki, Kayoko Taguchi, Minako Hongo, Kohei Takahashi, Yuki Shiko, Yoshiyuki Hirano, Eiji Shimizu

{"title":"Videoconference-Based Cognitive Behavioral Therapy in Medication-Treated Adults with Attention-Deficit/Hyperactivity Disorder: A Randomized, Assessor-Blinded, Controlled Trial.","authors":"Aiko Eto, Ayumu Endo, Tokiko Yoshida, Yoichi Seki, Kayoko Taguchi, Minako Hongo, Kohei Takahashi, Yuki Shiko, Yoshiyuki Hirano, Eiji Shimizu","doi":"10.1159/000546539","DOIUrl":null,"url":null,"abstract":"Introduction: Attention-Deficit/Hyperactivity Disorder (ADHD) is a neurodevelopmental disorder that frequently persists into adulthood. Pharmacotherapies are effective but have side effects and dropout risks. Videoconference-based Cognitive Behavioral Therapy (vCBT) has emerged as a promising intervention, particularly for improving treatment accessibility. This study aimed to evaluate the efficacy of vCBT in adults with ADHD compared to treatment-as-usual (TAU) using a randomized, assessor-blinded, controlled trial design.Methods: Thirty participants (aged 18-65 years) with ADHD were randomly assigned to either the 12-session individual vCBT intervention as an adjunct to TAU or TAU group. The primary outcome was the change in the total score on the ADHD Rating Scale-IV(ADHD-RS-IV) with adult prompts by a blinded assessor at 12 weeks from baseline. Secondary outcomes included self-reported measures of ADHD symptoms using the Conners' Adult ADHD Rating-Self-Report, quality of life (QOL) using the Euro QOL 5 Dimension-5 Level, functional impairment using the Sheehan Disability Scale, depression, anxiety, and self-esteem.Results: All of the participants received pharmacotherapy. Participants in the vCBT group (n=15) demonstrated a significantly greater reduction in ADHD-RS-IV total score than those in the TAU group (vCBT -9.02 vs. TAU 0.84, p = 0.0007, effect size -1.46). Significant improvements in self-reported inattention, hyperactivity, impulsivity, QOL, and work/school performance were observed in favor of vCBT.Conclusion: This study highlights the efficacy of vCBT as a viable and accessible intervention for adults with ADHD, particularly in reducing core symptoms and enhancing QOL and functional outcomes. vCBT is an important alternative treatment, especially for patients who remain symptomatic after pharmacotherapy.","PeriodicalId":20744,"journal":{"name":"Psychotherapy and Psychosomatics","volume":" ","pages":"1-25"},"PeriodicalIF":16.3000,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Psychotherapy and Psychosomatics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000546539","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PSYCHIATRY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Attention-Deficit/Hyperactivity Disorder (ADHD) is a neurodevelopmental disorder that frequently persists into adulthood. Pharmacotherapies are effective but have side effects and dropout risks. Videoconference-based Cognitive Behavioral Therapy (vCBT) has emerged as a promising intervention, particularly for improving treatment accessibility. This study aimed to evaluate the efficacy of vCBT in adults with ADHD compared to treatment-as-usual (TAU) using a randomized, assessor-blinded, controlled trial design.

Methods: Thirty participants (aged 18-65 years) with ADHD were randomly assigned to either the 12-session individual vCBT intervention as an adjunct to TAU or TAU group. The primary outcome was the change in the total score on the ADHD Rating Scale-IV(ADHD-RS-IV) with adult prompts by a blinded assessor at 12 weeks from baseline. Secondary outcomes included self-reported measures of ADHD symptoms using the Conners' Adult ADHD Rating-Self-Report, quality of life (QOL) using the Euro QOL 5 Dimension-5 Level, functional impairment using the Sheehan Disability Scale, depression, anxiety, and self-esteem.

Results: All of the participants received pharmacotherapy. Participants in the vCBT group (n=15) demonstrated a significantly greater reduction in ADHD-RS-IV total score than those in the TAU group (vCBT -9.02 vs. TAU 0.84, p = 0.0007, effect size -1.46). Significant improvements in self-reported inattention, hyperactivity, impulsivity, QOL, and work/school performance were observed in favor of vCBT.

Conclusion: This study highlights the efficacy of vCBT as a viable and accessible intervention for adults with ADHD, particularly in reducing core symptoms and enhancing QOL and functional outcomes. vCBT is an important alternative treatment, especially for patients who remain symptomatic after pharmacotherapy.

查看原文本刊更多论文

基于视频会议的认知行为疗法在药物治疗的成人注意力缺陷/多动障碍：一项随机、评估盲法、对照试验。

注意力缺陷/多动障碍（ADHD）是一种神经发育障碍，经常持续到成年。药物治疗是有效的，但有副作用和退出风险。基于视频会议的认知行为疗法（vCBT）已经成为一种很有前途的干预手段，特别是在提高治疗可及性方面。本研究旨在采用随机、评估盲、对照试验设计，评估vCBT与常规治疗（TAU）相比对成年ADHD患者的疗效。方法：30名患有ADHD的参与者（年龄在18-65岁）被随机分配到12个阶段的vCBT干预作为TAU的辅助或TAU组。主要结果是ADHD评定量表- iv （ADHD- rs - iv）总分的变化，由盲法评估者在基线后12周进行成人提示。次要结果包括使用Conners'成人ADHD评定自我报告的ADHD症状自我报告，使用Euro QOL 5维度5水平的生活质量（QOL），使用Sheehan残疾量表的功能损害，抑郁，焦虑和自尊。结果：所有患者均接受药物治疗。vCBT组（n=15）比TAU组（vCBT -9.02 vs. TAU 0.84, p = 0.0007，效应值-1.46）的参与者在ADHD-RS-IV总分上的降低显著更大。在自我报告的注意力不集中、多动、冲动、生活质量和工作/学习表现方面，观察到vCBT的显著改善。结论：本研究强调了vCBT作为一种可行且可获得的成人ADHD干预措施的有效性，特别是在减少核心症状和提高生活质量和功能结局方面。vCBT是一种重要的替代疗法，特别是对于药物治疗后仍有症状的患者。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Psychotherapy and Psychosomatics 医学-精神病学

CiteScore

29.40

自引率

6.10%

发文量

期刊介绍： Psychotherapy and Psychosomatics is a reputable journal that has been published since 1953. Over the years, it has gained recognition for its independence, originality, and methodological rigor. The journal has been at the forefront of research in psychosomatic medicine, psychotherapy research, and psychopharmacology, and has contributed to the development of new lines of research in these areas. It is now ranked among the world's most cited journals in the field. As the official journal of the International College of Psychosomatic Medicine and the World Federation for Psychotherapy, Psychotherapy and Psychosomatics serves as a platform for discussing current and controversial issues and showcasing innovations in assessment and treatment. It offers a unique forum for cutting-edge thinking at the intersection of medical and behavioral sciences, catering to both practicing clinicians and researchers. The journal is indexed in various databases and platforms such as PubMed, MEDLINE, Web of Science, Science Citation Index, Social Sciences Citation Index, Science Citation Index Expanded, BIOSIS Previews, Google Scholar, Academic Search, and Health Research Premium Collection, among others.